Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)

SHA:603707 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	662.89	1,024	1,210	1,389	658.55	493.55
Trading Asset Securities	767.72	1,055	681.99	1.3	259.8	845.79
Cash & Short-Term Investments	1,431	2,080	1,892	1,390	918.35	1,339
Cash Growth	-33.66%	9.94%	36.12%	51.34%	-31.43%	210.56%
Accounts Receivable	960.22	920.04	771.68	974.11	897.75	788.11
Other Receivables	277.39	273.46	230.88	241.94	167.88	107.21
Receivables	1,238	1,194	1,003	1,216	1,066	895.31
Inventory	3,397	3,675	4,158	5,616	4,894	4,457
Prepaid Expenses	-	13.17	11.98	8.46	7.98	10.11
Other Current Assets	206.4	84.42	196.99	64.14	43.62	65.9
Total Current Assets	6,272	7,046	7,262	8,294	6,930	6,768
Property, Plant & Equipment	1,205	1,197	1,235	1,198	827.42	532.83
Long-Term Investments	83.19	83.26	72.48	61.6	26.39	3.26
Goodwill	129.33	129.51	127.61	125.48	114.87	117.56
Other Intangible Assets	327.96	337.53	174.1	118.96	123.85	105.37
Long-Term Deferred Tax Assets	188.27	203.25	348.4	101.47	34.54	21.65
Long-Term Deferred Charges	658.84	459.55	294.24	94.62	77.65	55.52
Other Long-Term Assets	63.8	53.7	10.38	16.31	82.34	116.08
Total Assets	8,928	9,510	9,524	10,010	8,217	7,720
Accounts Payable	414.5	495.66	537.74	505.12	458.87	502.22
Accrued Expenses	182.61	207.11	294.85	88.15	64.56	47.26
Short-Term Debt	648.93	1,236	1,567	1,957	1,571	2,132
Current Portion of Long-Term Debt	2.2	8.21	505.45	0.42	-	-
Current Income Taxes Payable	33.47	3.72	29.31	0.44	8.73	17.42
Current Unearned Revenue	40.73	59.03	35.93	38.22	25.07	29.08
Other Current Liabilities	55.16	54.67	116.18	115.44	138.56	77.65
Total Current Liabilities	1,378	2,064	3,086	2,705	2,266	2,806
Long-Term Debt	826.55	824.16	512.37	997.36	480.75	1,132
Long-Term Leases	28.12	10.28	13.23	15.94	-	-
Long-Term Unearned Revenue	85.26	84.63	76.57	84.99	65.51	38.15
Long-Term Deferred Tax Liabilities	37.41	38.28	37.33	39.99	1.42	-
Total Liabilities	2,355	3,022	3,726	3,843	2,814	3,976
Common Stock	1,616	1,616	1,617	1,617	1,244	934.16
Additional Paid-In Capital	588.59	587.29	601.02	603.59	987.96	157.77
Retained Earnings	4,289	4,204	3,540	3,915	3,123	2,485
Treasury Stock	-	-	-27.75	-32.82	-47.3	-14.43
Comprehensive Income & Other	83.82	84.62	72.5	67.9	70.45	159.79
Total Common Equity	6,577	6,492	5,802	6,171	5,378	3,722
Minority Interest	-3.52	-3.51	-3.47	-3.47	24.84	22.12
Shareholders' Equity	6,573	6,488	5,798	6,167	5,403	3,745
Total Liabilities & Equity	8,928	9,510	9,524	10,010	8,217	7,720
Total Debt	1,506	2,079	2,598	2,971	2,051	3,264
Net Cash (Debt)	-75.18	1.13	-706.06	-1,581	-1,133	-1,925
Net Cash Per Share	-0.04	0.00	-0.45	-0.97	-0.72	-1.21
Filing Date Shares Outstanding	1,616	1,616	1,473	1,653	1,543	1,662
Total Common Shares Outstanding	1,616	1,616	1,473	1,653	1,543	1,662
Working Capital	4,894	4,981	4,175	5,589	4,663	3,962
Book Value Per Share	4.07	4.02	3.94	3.73	3.49	2.24
Tangible Book Value	6,120	6,025	5,500	5,926	5,139	3,500
Tangible Book Value Per Share	3.79	3.73	3.73	3.58	3.33	2.11
Buildings	-	472.9	481.48	448.47	268.49	164.68
Machinery	-	1,323	1,279	981.72	751.74	606.4
Construction In Progress	-	137.44	79.74	250.62	215.26	99.68

Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.